GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00516506 | Lung | IAC | establishment of vesicle localization | 32/2061 | 161/18723 | 6.53e-04 | 8.87e-03 | 32 |
GO:00516566 | Lung | IAC | establishment of organelle localization | 64/2061 | 390/18723 | 7.12e-04 | 9.50e-03 | 64 |
GO:00516486 | Lung | IAC | vesicle localization | 34/2061 | 177/18723 | 8.53e-04 | 1.09e-02 | 34 |
GO:00069008 | Lung | IAC | vesicle budding from membrane | 15/2061 | 61/18723 | 2.08e-03 | 2.07e-02 | 15 |
GO:00481937 | Lung | IAC | Golgi vesicle transport | 49/2061 | 296/18723 | 2.35e-03 | 2.28e-02 | 49 |
GO:005165012 | Lung | AIS | establishment of vesicle localization | 31/1849 | 161/18723 | 2.15e-04 | 4.36e-03 | 31 |
GO:005164812 | Lung | AIS | vesicle localization | 33/1849 | 177/18723 | 2.56e-04 | 4.96e-03 | 33 |
GO:000703011 | Lung | AIS | Golgi organization | 30/1849 | 157/18723 | 3.09e-04 | 5.63e-03 | 30 |
GO:005165612 | Lung | AIS | establishment of organelle localization | 59/1849 | 390/18723 | 6.08e-04 | 9.24e-03 | 59 |
GO:004819312 | Lung | AIS | Golgi vesicle transport | 46/1849 | 296/18723 | 1.32e-03 | 1.64e-02 | 46 |
GO:000690013 | Lung | AIS | vesicle budding from membrane | 14/1849 | 61/18723 | 2.09e-03 | 2.28e-02 | 14 |
GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
GO:005165610 | Oral cavity | OSCC | establishment of organelle localization | 239/7305 | 390/18723 | 2.46e-19 | 3.31e-17 | 239 |
GO:00160508 | Oral cavity | OSCC | vesicle organization | 189/7305 | 300/18723 | 2.40e-17 | 2.14e-15 | 189 |
GO:00068888 | Oral cavity | OSCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 97/7305 | 130/18723 | 1.42e-16 | 1.15e-14 | 97 |
GO:000690019 | Oral cavity | OSCC | vesicle budding from membrane | 49/7305 | 61/18723 | 4.73e-11 | 1.50e-09 | 49 |
GO:00069037 | Oral cavity | OSCC | vesicle targeting | 38/7305 | 45/18723 | 4.49e-10 | 1.19e-08 | 38 |
GO:00516509 | Oral cavity | OSCC | establishment of vesicle localization | 101/7305 | 161/18723 | 8.79e-10 | 2.17e-08 | 101 |
GO:00516489 | Oral cavity | OSCC | vesicle localization | 105/7305 | 177/18723 | 3.30e-08 | 6.30e-07 | 105 |
GO:00070307 | Oral cavity | OSCC | Golgi organization | 92/7305 | 157/18723 | 4.96e-07 | 7.27e-06 | 92 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MED9 | SNV | Missense_Mutation | novel | c.419N>A | p.Met140Lys | p.M140K | Q9NWA0 | protein_coding | deleterious(0.03) | possibly_damaging(0.478) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MED9 | SNV | Missense_Mutation | | c.124C>G | p.Gln42Glu | p.Q42E | Q9NWA0 | protein_coding | tolerated_low_confidence(0.78) | benign(0.015) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MED9 | SNV | Missense_Mutation | | c.424N>A | p.Glu142Lys | p.E142K | Q9NWA0 | protein_coding | deleterious(0.01) | possibly_damaging(0.771) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MED9 | SNV | Missense_Mutation | novel | c.221N>C | p.Lys74Thr | p.K74T | Q9NWA0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MED9 | SNV | Missense_Mutation | novel | c.256N>A | p.Asp86Asn | p.D86N | Q9NWA0 | protein_coding | deleterious(0.04) | benign(0.38) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MED9 | SNV | Missense_Mutation | | c.334N>A | p.Glu112Lys | p.E112K | Q9NWA0 | protein_coding | deleterious(0.01) | possibly_damaging(0.454) | TCGA-AX-A06H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
MED9 | SNV | Missense_Mutation | novel | c.304N>G | p.Ser102Gly | p.S102G | Q9NWA0 | protein_coding | tolerated(0.4) | benign(0.005) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MED9 | SNV | Missense_Mutation | rs137951481 | c.350N>T | p.Gln117Leu | p.Q117L | Q9NWA0 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MED9 | SNV | Missense_Mutation | | c.293N>A | p.Arg98His | p.R98H | Q9NWA0 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
MED9 | SNV | Missense_Mutation | novel | c.215N>A | p.Ile72Asn | p.I72N | Q9NWA0 | protein_coding | deleterious(0) | possibly_damaging(0.776) | TCGA-21-1081-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |